Pharvaris(PHVS)
Netherlands - LeidenBiotechnology
Focus: Pharvaris is a public biotech company focused on small-molecule therapies for rare diseases, primarily angioedema conditions. The company operates from Leiden, Netherlands with a lean pipeline concentrated on two lead assets.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Pharvaris?
AI assessmentStrong clinical pipeline and public status are offset by severe information asymmetry and minimal hiring — suitable only for mission-driven professionals willing to accept stability risk for rare-disease upside.
Why Work Here
- Public company status (NASDAQ: PHVS) provides equity liquidity and career visibility — meaningful for early-stage biotech professionals seeking exit optionality
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Growth
Lead asset in Phase 3 for two distinct angioedema indications with potential for orphan exclusivity and rapid market entry post-approval.
Icatibant
Help build intelligence for Pharvaris
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.